Hall Laurie J Trustee Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Hall Laurie J Trustee cut its stake in Pfizer Inc. (NYSE:PFE) by 2.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,246 shares of the biopharmaceutical company’s stock after selling 898 shares during the period. Hall Laurie J Trustee’s holdings in Pfizer were worth $875,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Olistico Wealth LLC purchased a new stake in Pfizer during the 2nd quarter worth about $25,000. Creekmur Asset Management LLC purchased a new stake in Pfizer during the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in Pfizer during the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new stake in Pfizer during the 4th quarter worth about $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Performance

PFE stock traded up $0.10 during trading on Tuesday, hitting $28.90. The company had a trading volume of 21,185,877 shares, compared to its average volume of 39,372,578. The firm has a market cap of $163.76 billion, a PE ratio of -481.67, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.19. The firm has a 50-day moving average price of $28.78 and a 200-day moving average price of $27.93. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the previous year, the company earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.81%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.